Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Account Payables
Amounts the company owes suppliers for goods and services received.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 247.7% from a year ago
Account payables stood at $391.08K at the end of Q1 FY2026, up 247.7% from a year earlier and down 99.9% from the prior quarter. Over 3 fiscal years it compounded at +1234.3% a year.
Context
- Account payables amounted to 3.6% of total assets at the end of Q1 FY2026, down 3.8 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +247.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 436.48M USD
- Year-over-year change
- +524480.0%
- 4-year CAGR
- +589.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 436.48M | +524480.0% |
| FY2024 | 2024-12-31 | 83.21K | -31.0% |
| FY2023 | 2023-12-31 | 120.51K | -34.4% |
| FY2022 | 2022-12-31 | 183.75K | -5.0% |
| FY2021 | 2021-12-31 | 193.47K | — |
Account Payables vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 account payables of $391.08K is the lowest of the 2 companies compared; the peer median is $2.67M.
- Its year-over-year change of +247.7% is the highest of 2, against a peer median of +212.2%.
- Account payables amounts to 3.6% of total assets for LIXT, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.67M | +212.2% | +38.7% | 8.7% | |
| Mar 2026 | $391.08K | +247.7% | +1234.3% | 3.6% | |
| Peer median (excluding LIXT) | $2.67M | +212.2% | +38.7% | 8.7% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.